Kairos Pharma (KAPA) Reports Interim PFS Benefit for ENV-105 in Phase 2 Prostate Cancer Trial

Kairos Pharma (KAPA) reported interim Phase 2 data showing ENV-105 plus apalutamide produced a statistically significant progression-free survival benefit versus apalutamide alone in metastatic castration-resistant prostate cancer, with median PFS of 17.7 months versus 2 months (P=0.0008). ENV-105 (carotuximab) is an antibody targeting CD105, a protein linked to therapy resistance and relapse. Based on the interim signal, the company amended the protocol to enroll patients earlier in disease progression — after a PSA increase following upfront androgen signalling inhibitor treatment — and will randomize them to enzalutamide alone or enzalutamide plus ENV-105. The change aims to expand the eligible population and ease enrollment, with Phase 2 completion targeted in or before the fourth quarter of 2027. CEO Dr. John Yu said the interim results provide an important clinical signal supporting the strategy of targeting drug-resistance mechanisms. KAPA has traded between $1.43 and $9.59 over the past year and closed Monday at $1.55. It was recently down 0.65% at $1.54.